

Product data sheet



MedKoo Cat#: 206141 Name: Solcitinib CAS#: 1206163-45-2 Chemical Formula: C ₂₂ H ₂₃ N ₅ O ₂ Exact Mass: 389.1852 Molecular Weight: 389.45	
Product supplied as:	Powder
Purity (by HPLC):	≥ 98%
Shipping conditions	Ambient temperature
Storage conditions:	Powder: -20°C 3 years; 4°C 2 years. In solvent: -80°C 3 months; -20°C 2 weeks.

1. Product description:

Solcitinib, also known as GSK2586184 or GLPG0778, is a Janus kinase 1 (JAK1) inhibitor. Solcitinib may be potential useful for treatment of psoriasis, systemic lupus erythematosus, ulcerative colitis. Solcitinib is greater than 10-fold selective for JAK1 over JAK2, JAK3, and TYK2.

2. CoA, QC data, SDS, and handling instruction

SDS and handling instruction, CoA with copies of QC data (NMR, HPLC and MS analytical spectra) can be downloaded from the product web page under “QC And Documents” section. Note: copies of analytical spectra may not be available if the product is being supplied by MedKoo partners. Whether the product was made by MedKoo or provided by its partners, the quality is 100% guaranteed.

3. Solubility data

Solvent	Max Conc. mg/mL	Max Conc. mM
DMF	2	5.14
DMSO	5	12.84
Ethanol	1	2.57

4. Stock solution preparation table:

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	2.57 mL	12.84 mL	25.68 mL
5 mM	0.51 mL	2.57 mL	5.14 mL
10 mM	0.26 mL	1.28 mL	2.57 mL
50 mM	0.05 mL	0.26 mL	0.51 mL

5. Molarity Calculator, Reconstitution Calculator, Dilution Calculator

Please refer the product web page under section of “Calculator”

6. Recommended literature which reported protocols for in vitro and in vivo study

In vitro study

To be determined

In vivo study

- De Vries LCS, Ludbrook VJ, Hicks KJ, D'Haens GR. GSK2586184, a JAK1 selective inhibitor, in two patients with ulcerative colitis. *BMJ Case Rep.* 2017 Aug 7;2017:bcr2017221078. doi: 10.1136/bcr-2017-221078. PMID: 28790099; PMCID: PMC5624036.
- Ludbrook VJ, Hicks KJ, Hanrott KE, Patel JS, Binks MH, Wyres MR, Watson J, Wilson P, Simeoni M, Schifano LA, Reich K, Griffiths CE. Investigation of selective JAK1 inhibitor GSK2586184 for the treatment of psoriasis in a randomized placebo-controlled phase IIa study. *Br J Dermatol.* 2016 May;174(5):985-95. doi: 10.1111/bjd.14399. Epub 2016 Apr 7. PMID: 26785220.

7. Bioactivity

Biological target:

Solcitinib is a JAK1 inhibitor with an IC₅₀ of 9.8 nM.

Product data sheet



In vitro activity

To be determined

In vivo activity

This study demonstrates that 12 weeks of treatment with solcitinib resulted in clinical improvement and was generally well tolerated in patients with moderate-to-severe plaque-type psoriasis. Improvement in itch and quality of life were observed at all doses of solcitinib with the greatest improvement seen in the 400-mg dose group. The incidence of adverse events was similar across treatment groups; there was no relationship between frequency of adverse effects and solcitinib dose.

Reference: Br J Dermatol. 2016 May;174(5):985-95. <https://pubmed.ncbi.nlm.nih.gov/26785220/>

Note: The information listed here was extracted from literature. MedKoo has not independently retested and confirmed the accuracy of these methods. Customer should use it just for a reference only.